المؤلفون: Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A

المصدر: Cancer Management and Research, Vol Volume 13, Pp 9379-9389 (2021)

مصطلحات موضوعية: hepatocarcinoma, sorafenib, lenvatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/real-life-clinical-data-of-lenvatinib-versus-sorafenib-for-unresectabl-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/d67257cd6b204d2b8db488af802f77d2